A recent study sought to examine the course of these patients after the age of 40, and to identify possible risk factors for a worse prognosis.
There has been an increase in life expectancy for individuals with congenital heart disease (CHD), including both simple defects as well as more complex ones, with the median age now at 40 years.
While patients with both CHD and pulmonary arterial hypertension (PAH) continue to have the worst morbidity and mortality, this group, too, is living longer than before. A recent study sought to examine the course of these patients after the age of 40, and to identify possible risk factors for a worse prognosis.
Data regarding these older patients are limited, said the authors, writing in the Journal of Clinical Medicine.
The retrospective, single-center study in Germany included all patients with a diagnosis of PAH-CHD under follow-up at a cardiology center who were 40 years of age or older at any point between January 2005 and December 2018. The primary endpoint was all-cause mortality.
The diagnosis was established and confirmed by echocardiography, cardiac MRI, and/or cardiac catheterization.
Underlying CHD was classified as follows:
Left and right ventricular systolic function was graded semi-quantitatively as normal, or mildly, moderately or severely impaired. Arrhythmias included any type of supraventricular or ventricular arrhythmia requiring treatment.
The study included 65 patients (67.7% female, mean age 45.19 [6.75] years); of these, 46 (70.8%) had a shunt lesion; 12 (18.5%) had PAH associated with complex congenital heart defects; 7 (10.8%) had segmental pulmonary hypertension due to major aorto-pulmonary collaterals. Down syndrome was present in 13 patients (20.0%).
During a median follow-up of 4.2 years (interquartile range [IQR] 1.2-7.5), 16 patients (24.6%) died; 3 were from cardiac causes; 1 from respiratory failure; 1 from a cerebrovascular accident; and 11 from unknown causes.
About one-third of the patients required unplanned/emergency hospital admissions.
On univariate analysis, NT-proBNP (log), creatinine, and a previous history of ventricular arrhythmias were predictors of all-cause mortality.
Upon multivariate analysis, only NT-proBNP (log) (HR, 4.1; 95% CI, 1.2-14.4, P = .029) and creatinine (HR, 16.3; 95% CI, 2.2-118.7; P = .006) remained as independent predictors of all-cause mortality.
The study had several limitations, including a small sample size, the retrospective nature of the work, and some missing variables, such as cause of death for 11 patients and results from the 6-minute walk test.
"Close surveillance, including regular blood analysis, is necessary to identify patients at risk," the authors concluded.
Reference
Maurer SJ, Stöckemann K, Pujol C, Hörer J, Ewert P, Tutarel O. Pulmonary arterial hypertension associated with congenital heart disease in adults over the age of 40 years. J. Clin. Med. 2020; 9(12), 4071. doi:10.3390/jcm9124071
Family Key to PAH Care for Women, but Gaps Remain
June 18th 2025This study highlights the vital role of caregivers in supporting women living with pulmonary arterial hypertension (PAH) and underscores the need to enhance caregiver support and address unmet needs to improve patient outcomes.
Read More
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More